I’ll be headed into Boston on Wednesday for this year’s Endpoints 11. And this year, we have some very interesting plans to celebrate our selection of 11 up-and-coming biotechs with Very Big Plans.
Some years ago, when I was orchestrating a similar project for another biopharma newsgroup you may have heard of, the marketing manager arranged to have me host the event at a crowded Chicago bar. The drinks flowed fast, the masses came to talk — to each other — and I was pretty much drowned out by the rough orchestra of drunk noise.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.